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ABSTRACT
Vascularization is important in wound healing and essential for tissue ingrowth into porous tissue-
engineering matrices. Furthermore, peri-implant tissue vascularization is known to be important for the
functionality of subcutaneously implanted biosensors (e.g., glucose sensors). As a first exploration of the use
of deoxyribonucleic acid (DNA)-based coatings for the optimization of biosensor functionality, this study
focused on the effect of DNA-based coatings functionalized with vascular endothelial growth factor (VEGF)
on in vitro endothelial cell behavior and vascularization of the peri-implant tissue in vivo. To that end, DNA-
based coatings consisting of poly-D-lysine and DNA were functionalized with different amounts of VEGF
(25 and 250 ng) and compared to non-coated controls and non-functionalized DNA-based coatings. The
results demonstrated the superiority of VEGF-functionalized DNA-based coatings in increasing endothe-
lial cell proliferation and migration in vitro over non-coated controls and non-functionalized DNA-based
coatings. In vivo, a significant increase in vascularization of the peri-implant area was observed for VEGF-
functionalized DNA-based coatings. Because no dosage-dependent effects were observed, future experi-
ments should focus on optimizing VEGF concentration for this purpose. Additionally, the administration
of VEGF in combination with other (pro-angiogenic) factors should be considered.
INTRODUCTION
AN IMPORTANT PHYSIOLOGICAL ASPECT of healing aroundbiomaterials is vascular development. For tissue-
engineering matrices, particularly those that are pre-seeded
with cells, fast development of a vascular network is re-
quired for tissue ingrowth and cell survival. Also, for solid
devices such as subcutaneously implantable biosensors, the
development of a contiguous vascular network is important
for their functionality.1,2 For instance, previous studies
have demonstrated that the formation of a largely avascular
fibrous tissue capsule and the resulting increased diffusion
distance between sensor and blood supply to the sensor sur-
rounding tissue diminishes the responsiveness of implanted
biosensors to fluctuations in analytes in the interstitial
fluid.1,2 Furthermore, Gerritsen et al. showed that inflam-
matory cells and low-molecular-weight serum components
influence the performance of amperometric glucose sensors.3
The basis for these findings was the secretion of enzymes
by stimulated granulocytes, which consumed the hydrogen
peroxide formed by the oxidation of glucose, and the for-
mation of a diffusional barrier for glucose and the inhibi-
tion of glucose oxidase activity by serum components.
Consequently, the authors of these publications suggested
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that biosensor functionality is likely to improve if the vas-
cularity in the direct vicinity of the device is increased and
inflammatory responses to the device are minimal.
The development of the vasculature depends on two pro-
cesses (vasculogenesis and angiogenesis), which are respon-
sible for de novo vessel formation and sprouting from
already existing vessels, respectively.4 Therapeutical mod-
ulation of vascular supply, however, is limited to angiogen-
esis, because vasculogenesis is believed to occur only during
early embryogenesis. Angiogenesis is a complex process
that involves subtle interactions between cells, extracellular
matrix components, and regulatory molecules. Decisive
steps in this process are the localized proteolytic degrada-
tion of the subendothelial basement membrane, migration
of endothelial cells, the formation of sprouts, remodeling
of extracellular matrix, and the formation of anastomoses,
which together precede the establishment of blood flow.5
The delivery of growth factors with pro-angiogenic action is
a potentially powerful tool in control over vascular devel-
opment. A widely used pro-angiogenic growth factor in
tissue engineering is vascular endothelial growth factor
(VEGF).6 VEGF affects endothelial cells through positive
effects on proliferation, migration, tubule formation, sur-
vival, and integrin expression.7
To increase vascularity around subcutaneously implanted
biosensors, we hypothesized that VEGF functionalization
of deoxyribonucleic acid (DNA)-based coatings could be
beneficial. It has been demonstrated that these coatings,
whose generation is based on the layer-by-layer deposition of
cationic poly-D-lysine (PDL) or poly(allylamine hydrochlo-
ride) with anionic DNA,8 are fully histocompatible upon
subcutaneous implantation, showing no adverse reactions in
terms of inflammation and wound healing.9,10 Furthermore, it
was shown that these DNA-based coatings are suitable for
functionalization with bone morphogenetic protein 2 (BMP-
2), an osteo-inductive factor, using different loading modal-
ities and that this factor retained its biological activity.11
Another important feature of the fabrication method of these
DNA-based coatings is its simplicity, which allows a wide
variability of substrate materials (e.g., ceramics, metals, and
polymers) with almost unrestricted substrate geometry.12
In view of the described disadvantageous effects of lack of
vascularity on biosensor functionality, we hypothesized that
VEGF functionalization of DNA-based coatings would be
beneficial for the vascularization of the peri-implant tis-
sue. Consequently, the aim of this study was to evaluate the
effect of VEGF-functionalized DNA-based coatings on en-
dothelial cell behavior in vitro and vascular development
in vivo. Therefore, [PDL/DNA]5 coatings on glass substrates
were functionalized with a small (25 ng) or large (250 ng)
amount of VEGF to study dosage-dependent effects. These
VEGF-functionalized DNA-based coatings, as well as non-
functionalized coatings and non-coated controls, were used in
an in vitro experiment to study the proliferation, migration,
and morphology of endothelial cells. Additionally, these four
types of substrates were implanted in the backs of rats in an
in vivo animal model to study vascular development in the
direct vicinity of the implants.
MATERIALS & METHODS
Materials
Polyanionic salmon DNA (300 bp/molecules; sodium
salt) was kindly provided by Nichiro Corporation (Kawa-
saki, Japan). Potential protein impurities in the DNA were
checked using the bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL) and were measured to be below 0.20%
w/w (data not shown). Polycationic polyelectrolyte PDL
(mw 30,000–70,000) was purchased from Sigma (Sigma-
Aldrich Chemie B.V., Zwijndrecht, the Netherlands). All
materials were used without further purification.
Substrate preparation and cleaning
Disc-shaped glass substrates (12 mm diameter; 1.5 mm
thickness; Waldemar-Knittel Glasbearbeitung GmbH, Braun-
schweig, Germany) were cleaned in Piranha solution (hy-
drogen peroxide (H2O2, 30% aqueous solution)/sulfuric acid
3:7 v/v) to completely remove all traces of organic materials
at the surface and to increase the wettability of the surface.
Subsequently, the substrates were thoroughly rinsed with
ultra-pure water from a Millipore system (resistivity 18.2
MWcm; Millipore B.V., Amsterdam, The Netherlands) and
dried using a pressurized air stream.
Generation of multilayered DNA coatings
DNA coatings were generated using layer-by-layer depo-
sition, as described previously.8 Briefly, the substrates were
immersed in an aqueous solution of PDL (0.1 mg/mL) for
30 min, allowing sufficient time for the adsorption of the
first cationic polyelectrolyte layer onto the substrates. Subse-
quently, substrates were washed in ultra-pure water (5 min;
continuous water flow) and dried using a pressurized air
stream. Thereafter, substrates were alternately immersed in
an anionic aqueous DNA solution (1 mg/mL) and the PDL
solution for 7 min each, with intermediate washing in ultra-
pure water and subsequent drying using a pressurized air
stream to obtain final coating architecture of [PDL/DNA]5.
(The number indicates the number of double layers.)
Experimental groups
Non-coated substrates and [PDL/DNA]5-coated substrates
were sterilized using an ultraviolet treatment (254 nm; 4 h).
Subsequently, VEGF functionalization of [PDL/DNA]5-
coated substrates was carried out as described below. The
experimental groups used in this study were controls (non-
coated glass substrates), [PDL/DNA]5 (glass substrates with a
[PDL/DNA]5-coating), [PDL/DNA]5-VEGF25 ([PDL/DNA]5-
coated glass substrates with 25 ng VEGF), and [PDL/DNA]5-
VEGF250 ([PDL/DNA]5-coated glass substrates with 250 ng
VEGF).
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Functionalization with VEGF
Recombinant rat VEGF (rrVEGF164; 164 amino acids;
Department of Biochemistry, Radboud University Nijme-
gen Medical Center, Nijmegen, The Netherlands) was se-
rially diluted in phosphate-buffered saline (PBS), after
which 25 or 250 ng of VEGF was applied in 10-ml aliquots
to the sterilized [PDL/DNA]5-coated substrates. Because of
the iso-electric point of VEGF (pI 8.5),13 it is positively
charged at neutral pH and shows similar interaction with
the negatively charged DNA top-layer in the multilayered
structure as observed previously for BMP-2.11 The solvent
was evaporated during incubation at 378C.
In vitro experiments
Cell culture and seeding. Human umbilical vein endo-
thelial cells (HUVECs; PromoCell GmbH, Heidelberg, Ger-
many) were expanded in growth medium containing basic
fibroblast growth factor (1 ng/mL), endothelial cell growth
supplement/heparin (0.4% v/v), epidermal growth factor
(0.1 ng/mL), hydrocortisone (1 mg/mL), phenol red (0,62
ng/mL), and fetal calf serum (FCS; 2% v/v) (PromoCell
GmbH). To increase cell attachment, before cell seeding the
experimental substrates were incubated for 1 h at 378C in
assay medium (AM; alpha-minimal essential medium; Gibco,
Invitrogen Corporation, Breda, The Netherlands), supple-
mented with 10% v/v FCS and gentamycin (50mg/mL)). For
each experimental run, cells were seeded at a density of
20103 cells/cm2 and maintained in AM to exclude potential
effects of factors supplemented in growth medium. Medium
was refreshed at 1 day after cell seeding and thereafter 3 times
per week.
Proliferation of endothelial cells. At selected times after
cell seeding (1, 4, 7, and 10 days post-seeding), cells were
trypsinized and counted using a Coulter counter (Beckman
Coulter Inc., Fullerton, CA, USA). Data were obtained from
2 independent experimental runs with triplicate samples for
each condition and time point (n = 3).
Morphology of endothelial cells. Parallel to the prolifer-
ation assays, 2 independent runs to study endothelial cell
morphology were conducted. In each of these runs, 2 exper-
imental samples for each condition at each time point were
seeded with HUVECs at a density of 20103 cells/cm2 and
incubated for 3 and 10 days. After these culture periods, cell
layers were washed twice with PBS, fixed with 2% glutar-
aldehyde, and dehydrated in a graded series of ethanol. Fi-
nally, cell layers were dried using tetramethylsilane, sputter-
coated with gold, and morphologically examined using a
scanning electron microscope (JEOL 6310, JEOL Europe
BV, Nieuw-Vennep, The Netherlands).
Migration of endothelial cells. The migrational behavior
of endothelial cells (HUVECs) was assessed in 1 experi-
mental run using a commercially available in vitro endo-
thelial cell migration assay platform (BD BioCoat Angio-
genesis System: Endothelial Cell Migration; BD Biosciences,
Bedford MA), according to the manufacturer’s instructions.
The assay measures the migration of cells (located in an
insert) through a microporous membrane toward medium
(with or without supplement) in the well. Briefly, [PDL/
DNA]5-VEGF25 and [PDL/DNA]5-VEGF250 experimental
substrates (n¼ 3) were placed in a 24-well plate and incu-
bated with 1 mL AM for 1, 4, 7, 10, and 14 days. At each time
point, the medium was collected, after which fresh medium
was added to each experimental substrate for subsequent
VEGF release. Collected medium was stored at808C until
use in the migration kit. For the assay, 225mL of collected
medium was added in duplicate in a 96-well plate. Sub-
sequently, HUVECs were added to each insert (25103
cells in 75ml of AM 2% bovine serum albumin (BSA)),
whose content was separated from the well volume using a
fluorescence-blocking microporous (3mm) poly(ethylene
terephthalate) (PET) membrane. The migration of HUVECs
was quantified using post-labeling of the cells with calcein-
AM and subsequent fluorescence measurements (excitation
485 nm, emission 530 nm) of the PET membrane after 22 h of
incubation. For comparison, the migration of endothelial
cells toward medium with known amounts of VEGF (stan-
dards: range 0–250 ng/mL) was measured. Data were cor-
rected for fluorescence values of blanks (inserts without
endothelial cells) and expressed as fold migration, which is
set at 1 for the lowest VEGF concentration of the standard.
In vivo experiment
Animals and implantation procedure. For implantation,
200- to 250-g male Wistar rats were used. The animals were
housed in the central animal facility at the Radboud Univer-
sity Nijmegen Medical Center (Nijmegen, The Netherlands),
observing all national guidelines for care and use of laboratory
animals. The animals received chow and water ad libitum.
Before the implantation procedure, approval was obtained
from the ethical committee for animal experiments at the
Radboud University Nijmegen (KUNDEC #2003-14).
Surgery was performed under general inhalation anesthe-
sia with nitrous oxide, oxygen, and isoflurane. The animals
were immobilized and placed in a ventral position. Subse-
quently, the dorsal skin of the animals was shaved, washed,
and disinfected with povidone-iodine. On each side of
the vertebral column, 2 paravertebral incisions were made
(*10 mm), after which a subcutaneous pocket was created
using blunt dissection with scissors lateral to each incision.
The insertion of substrates was performed such that the
VEGF-functionalized side faced the dorsal skin. After in-
sertion of an implant, the skin was closed using skin staples
(Agraves; InstruVet C.V., Cuijk, The Netherlands). A total
of 64 implants (16 implants of each group) were distributed
in 16 rats (4 implants per rat) according to a Latin square
randomization scheme.
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Implant retrieval and histological preparations. At the
end of each implantation period (1 or 3 weeks), 8 rats were
killed using CO2-suffication. Subsequently, tissue-covered
specimens (n¼ 8 for each implant type and implantation
period) were collected, the implants excised from the tissue
capsule and checked for potential tissue remains using
scanning electron microscopy as described previously,9,10
and the implant-surrounding tissue processed for embedding
in paraffin. Paraffin sections were analyzed histologically
(hematoxylin/eosin staining) to obtain complete descrip-
tions of the observed thin sections.
Immunohistochemistry. In parallel with the hematoxylin/
eosin staining, paraffin sections were used for immunohis-
tochemical staining using an anti-alpha smooth muscle actin
(anti-aSMA) antibody. Among other tissues, a-SMA is pres-
ent in blood vessel walls14 and myofibroblasts,15 and its ex-
pression was used to determine the total number of blood
vessels in the peri-implant area. Deparaffinated sections were
treated with 3% H2O2 in PBS for 20 min to block endogenous
peroxidase, fixed with 4% formalin, blocked with 5% BSA
(Sigma), incubated with monoclonal immunoglobulin G2a
mouse anti-aSMA (1:1600; Sigma), and incubated with
biotinylated donkey anti-mouse secondary antibody (1:500;
Jackson Laboratories, West Grove, PA). Staining was per-
formed with a biotin-streptavidin detection system (Vectra
Elite kit; Vector Laboratories, Burlingame, CA) for 45 min.
Positivecontrols (ratbrain tissuesectionswithpositivestaining
in previous immunohistochemical procedures) and negative
controls (1% BSA in PBS) were included.
Histological and histomorphometrical evaluation. A light
microscope (Leica Microsystems AG, Wetzlar, Germany)
was used for histological evaluation of the hematoxylin/
eosin-stained sections. Immunohistochemically (anti-aSMA)
stained sections were used for histomorphometrical evalua-
tion of the number of blood vessels per area. Computer-based
image analysis techniques (Leica Qwin Pro-image analysis
software; Leica, Wetzlar, Germany) were used to determine
the following parameters in digital images of immuno-
histochemically stained sections:
- region of interest (ROI): the connective tissue area at
the dorsal site of the implant (excluding muscle and
fat tissue) in a digital image of approximately 700
560 mm (original magnification 20; Fig. 1).
- number of blood vessels (BV): number of positively
stained vascular structures (blood vessels) within the
ROI.
The values obtained with these parameters were used to
determine the vascularization (vessel density, VD):
VD¼BV=ROI
For each implant-surrounding tissue section, VD was
determined by averaging the numbers of counted vascular
structures per ROI of 3 digital images (at 20magnifica-
tion) per tissue section. Eight average VDs were obtained
for each group at each time period.
Statistical analysis
All measurements were statistically evaluated using
GraphPad Instat software (version 3.05; GraphPad Instat,
San Diego, CA). Statistical analysis was performed using
a one-way analysis of variance with a post hoc Tukey-
Kramer multiple comparison test for cell proliferation, mi-
gration, and vascularization at individual implantation
periods. Vascularization for individual groups and pooled
groups at different implantation periods was assessed using
FIG. 1. Schematic overview of histomorphometric parameters
in immunohistochemically (anti-alpha smooth muscle actin) stained
sections. (A) Representative image showing the original location
of the implant (I), the surrounding fibrous capsule (Cap), the
connective tissue (C), and muscle tissue (M). (B) Qwin Pro-image
analysis software was used to indicate the region of interest (ROI),
after which the number of positively stained vascular structures
within the ROI was counted. Color images available online at
www.liebertpub.com /ten.
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Proliferation of endothelial cells. The 2 independent runs
of endothelial cell proliferation showed comparable results.
The results of one of these runs are presented in Figure 2.
Initial cell numbers (on day 1) showed that comparable
numbers of endothelial cells attached to the experimental
substrates after cell seeding. From day 4, 7, and 10, how-
ever, endothelial cells on [PDL/DNA]5-VEGF25 and [PDL/
DNA]5-VEGF250 showed statistically significantly more
cells than controls and [PDL/DNA]5 ( p< 0.05, p< 0.01,
and p< 0.001 for days 4, 7, and 10, respectively). Whereas
cell numbers on [PDL/DNA]5-VEGF25 and [PDL/DNA]5-
VEGF250 increased over time, those on controls and [PDL/
DNA]5 were constant over time and did not differ statisti-
cally from each other ( p> 0.05). Furthermore, no statisti-
cally significant differences were found between [PDL/
DNA]5-VEGF25 and [PDL/DNA]5-VEGF250 at individual
time points ( p> 0.05).
Morphology of endothelial cells. The morphological
appearance of the endothelial cells (HUVECs) on the exper-
imental substrates was evaluated using scanning electron
microscopy. In Figure 3, representative images of endothe-
lial cells cultured for 4 days on control and [PDL/DNA]5-
VEGF250 substrates are depicted. Endothelial cells showed
a similar morphology on all types of experimental substrates.
The cells exhibited a flat appearance and had several cellular
extensions. After 4 and 10 days of cell culture, a visibly
greater number of cells was observed on [PDL/DNA]5-
VEGF25 and [PDL/DNA]5-VEGF250 than on controls and
[PDL/DNA]5.
Migration of endothelial cells. An in vitro migration assay
was used to study the effect of VEGF release from VEGF-
functionalized DNA-based coatings on endothelial cell
migration. The migration of endothelial cells toward a con-
centration gradient of VEGF standards (rrVEGF164 in AM;
range 0–250 ng/mL) is depicted in Figure 4 (inset) and was
used to obtain information on the VEGF release from VEGF-
functionalized DNA-based coatings. The results show that
VEGF significantly increased endothelial cell migration at
concentrations ranging from 1.25 to 100 ng/mL ( p< 0.05).
In contrast, a VEGF concentration of 250 ng/mL had no ef-
fect on endothelial cell migration.
Collected medium from the incubation of [PDL/DNA]5-
VEGF25 and [PDL/DNA]5-VEGF250 experimental sub-
strates showed that these media also increased endothelial
cell migration (Fig. 4). The increased effect on endothelial
cell migration was observed in medium that had been col-
lected from 1 to at least 14 days after initiation of incubation.
No statistically significant differences were observed be-
tween media collected from [PDL/DNA]5-VEGF25 and
[PDL/DNA]5-VEGF250 experimental substrates (p> 0.05).
In vivo experiment
General observations. All 16 rats in the animal experi-
ment remained in good health during the implantation periods
FIG. 2. Proliferation of human umbilical vein endothelial cells
(HUVECs) on experimental substrates. Results are shown as
means standard deviations of triplicate samples for one represen-
tative experiment out of two. *p< 0.05 compared with controls,
**p< 0.01 compared with controls, ***p< 0.001 compared with
controls.
FIG. 3. Morphology of human umbilical vein endothelial cells (HUVECs) after culture on experimental substrates after 4 days. Rep-
resentative scanning electron microscopy images of HUVECs on (A) control and (B) poly-D-lysine/deoxyribonucleic acid ([PDL/DNA])5-
vascular endothelial growth factor (VEGF)250 substrates, showing a flat morphology of endothelial cells with several cellular extensions.
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and did not show any wound complications after surgery. At
1 week after implantation, a total of 32 implants were re-
trieved. At retrieval, a thin fibrous capsule surrounded all
subcutaneous implants. None of the implant sites showed
macroscopic signs of inflammation or adverse tissue reaction.
Similarly, at 3 weeks after implantation, another 32 implants
were retrieved, all of which were surrounded by a thin fibrous
capsule and devoid of any macroscopic signs of inflammation
or adverse tissue reactions.
Descriptive histological evaluation. Scanning electron
microscopic examination of the excised implants showed
that implants were sparsely covered with proteinaceous-like
deposits, which were not identifiable as cellular material
(data not shown). Gross evaluation of the hematoxylin/eosin-
stained sections of the implant-surrounding tissue capsules
after1 weekofsubcutaneous implantationrevealeda relatively
uniform tissue response to all implants (Fig. 5). Tissue at the
dorsal side of the implants consisted of a fibrous capsule,
connective tissue, muscle tissue, and the dermis. Occasion-
ally, fat tissue was observed in the vicinity of the implants.
The fibrous capsule was immature, reflected by the absence
of flat fibrocytes at the implant side of the capsule. Few or no
inflammatory cells could be observed at the implant–capsule
interface or in the direct vicinity of the implants.
After 3 weeks of subcutaneous implantation, a tissue re-
sponse similar to that after 1 week was observed for all im-
plants. However, the fibrous tissue capsules had matured, as
indicated by the presence of fibrocytes with a flat appearance
within the tissue capsules (Fig. 6A, B). The thickness of the
fibrous capsules was within the range of 5 to 30 fibroblasts,
independent of implant type. No gross differences in tissue
response were observed, depending on implant type.
Histomorphometrical evaluation of vascularization at the
dorsal site of the implant. For the evaluation of the vas-
cularization of the connective tissue at the dorsal site of the
implants, paraffin sections were subjected to immunohis-
tochemical techniques using a monoclonal antibody against
aSMA. Representative images of the stained sections are
presented in Figure 6C and D. Positive staining was ob-
served for vascular structures and fibrous capsules. A dif-
ference was observed in immunohistochemical staining of
fibrous capsules after 1 and 3 weeks of implantation, with
greater staining in the more-mature fibrous capsules at 3
weeks after implantation.
Histomorphometrically, the vascularity in the tissue at the
dorsal site of the implant was calculated by determining the
ROI and the number of positively stained vascular structures
(blood vessels) within this ROI. The histomorphometrical
results are presented in Table 1. The average ROI of the
digitally imaged area in all experimental groups ranged from
0.25 to 0.28 mm2. Vascularization (VD; # vascular structures/
mm2 ROI) of the analyzed areas showed a tendency to in-
crease in both groups of VEGF-functionalized DNA-based
coatings. However, no statistically significant differences
between the individual experimental groups at individual im-
plantation periods were found ( p> 0.05). On the other hand,
pooled data of VEGF-functionalized experimental implants
([PDL/DNA]5-VEGF25þ [PDL/DNA]5-VEGF250) and non-
functionalized implants (controlsþ [PDL/DNA]5) showed sig-
nificantly greater vascularization in the peri-implant tissue of
VEGF-functionalized implants (p< 0.05). Vascularization in
the peri-implant tissue was in the range of 102 to 155 and 66 to
142 vascular structures per mm2 at 1 and 3 weeks after sub-
cutaneous implantation, respectively. No statistically signifi-
cant differences were found for individual experimental groups
at different implantation periods, except for [PDL/DNA]5,
which showed less vascularization after 3 weeks than after
1 week.
DISCUSSION
This study was initiated to study the effect of functiona-
lization of a DNA-based coating with the pro-angiogenic
factor VEGF on endothelial cell behavior in vitro and vas-
cularization of the peri-implant tissue in vivo. In vitro, the
effects of DNA-based coatings with small (25 ng) and large
(250 ng) amounts of VEGF on endothelial cell proliferation,
morphology, and migration were evaluated and compared
with those of non-coated controls and non-functionalized
DNA-based coatings. In vivo, these 4 types of substrates were
implanted subcutaneously in the backs of rats. After im-
plantation periods of 1 and 3 weeks, the vascularization in the
direct vicinity of the implants was determined. The results of
the in vitro experiments indicate that the pro-angiogenic
factor VEGF remains biologically active within the functio-
nalized DNA-based coatings, as reflected by a greater effect
of functionalized DNA-based coatings on endothelial cell
FIG. 4. Migration of human umbilical vein endothelial cells
(HUVECs) in response to recombinant rat VEGF (rrVEGF)164
release from vascular endothelial growth factor (VEGF)-func-
tionalized experimental substrates (poly-D-lysine/deoxyribo-
nucleic acid/deoxyribonucleic acid ([PDL/DNA])5-VEGF25 and
[PDL/DNA]5-VEGF250). Inset shows migration effects of different
concentrations of VEGF (rrVEGF164; range 0–250 ng/mL; *p<
0.05 compared with 0 ng/mL).
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proliferation and migration than of non-coated controls and
non-functionalized DNA-base coatings. Furthermore, greater
vascularization of the peri-implant tissue surrounding VEGF-
functionalized DNA-based coatings was observed in vivo.
In an attempt to optimize the functionality of biosensors,
this study was a first exploration of the use of DNA-based
coatings for this purpose in view of the feasibility of their
being functionalized with desired factors.11 Consequently,
this study focused on functionalization of DNA-based coat-
ings with the pro-angiogenic factor VEGF, and experiments
were aimed at elucidating in vitro effects on endothelial cells
and in vivo effects on implant site vascularization. The type
of DNA-based coating was limited to [PDL/DNA]5, although
the fabrication and characterization of different types of DNA-
based coatings have been described previously.8 The choice
for a single type of DNA-based coatings is justified, because
previous experiments have demonstrated that cellular and
histological responses to different types of DNA-based
coatings were similar.8–10,16 The amount of VEGF needed for
biological activity in vitro and in vivo appears to be unclear.
Amounts as small as 10 ng have shown biological effects
in vitro,17 whereas others used micrograms to induce bio-
logical effects of VEGF.18,19 It is likely that the amount
needed for biological effects on vascular development are
dependent on factors such as type of VEGF, release profile,
and animal model. For our experiments, as a first approach,
2 amounts (25 and 250 ng) were chosen with a 10-fold dif-
ference.
The greater proliferation of endothelial cells on VEGF-
functionalized DNA-based coatings in the in vitro experi-
ments demonstrates that the pro-angiogenic factor VEGF
remainsbiologicallyactive.Similarresultswererecentlyfound
for the osteo-inductive factor BMP-2, which was superficially
loaded onto DNA-based coatings and accelerated the differ-
entiation of osteoblast-like cells.11 Furthermore, our prolif-
eration experiments demonstrated that the presence of VEGF
is a prerequisite for endothelial cells (HUVECs) to proliferate,
because cells cultured on controls and DNA-based coatings
did not proliferate. Additionally, no negative effects of DNA-
based coatings on endothelial cells were observed, which
corroborates observations of others using polyelectrolyte
multilayers as a substrate for endothelial cells.20,21
The efficacy of biomaterial devices in combination with
growth factors depends partly on the availability of the
growth factors for sensible cells. For instance, a minimal
release of BMP-2 from a porous calcium phosphate scaffold
appeared to be sufficient for enhanced bone formation.22
However, for our purpose, an increasing effect of VEGF on
FIG. 5. Representative histological sections (hematoxylin/eosin staining) of implant-surrounding tissue 1 week after subcutaneous
implantation in the back of rats. (A, B) Overview showing the fibrous tissue capsule with connective tissue, a muscle layer, and dermis
at the dorsal side of the implant. (C, D) Magnification of A and B showing the thin fibrous capsule and connective tissue at the dorsal
side of the implant. Color images available online at www.liebertpub.com /ten.
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vascularity in the peri-implant area in our in vivo experiment
was likely to be dependent on release of the factor from the
DNA-based coating. Additionally, the increased effect on
the proliferation of endothelial cells observed on VEGF-
functionalized DNA-based coatings does not necessitate
factor release, because bound factor might also be available
for adherent cells. In light of this, the results of the migration
assay indicate a continuous release of VEGF from VEGF-
functionalized DNA-based coatings. Although this assay does
not provide detailed information on exact amounts of VEGF
released at each incubation period, it shows that released
amounts are sufficient for the chemotaxis of endothelial cells.
On the basis of the release profiles of BMP-2 from [PDL/
DNA]5 coatings and the comparable iso-electric point and
molecular weight of BMP-2 and VEGF,13 it can be specu-
lated that VEGF release profiles also show an initial burst
TABLE 1. HISTOMORPHOMETRICAL ANALYSIS OF VASCULARIZATION AT THE DORSAL SITE
OF SUBCUTANEOUSLY INSERTED IMPLANTS (N¼ 8)
Implantation
time (weeks)








[PDL/DNA]5-VEGF25 3 142 54
[PDL/DNA]5-VEGF250 136 65
p< 0.05.
PDL, poly-D-lysine; DNA, deoxyribonucleic acid; VEGF, vascular endothelial growth factor.
 

FIG. 6. Representative histological sections of implant-surrounding tissue 3 weeks after subcutaneous implantation in the back of rats.
(A, B) Hematoxylin/eosin staining showing the fibrous tissue capsule with connective tissue at the dorsal side of the implant. (C, D)
Immunohistochemical staining (anti-alpha smooth muscle actin) showing the blood vessels in the connective tissue at the dorsal side of
the implant. Color images available online at www.liebertpub.com /ten.
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release followed by a sustained release for several weeks.
This would indicate that the initial VEGF burst release would
approximate 17 and 170 ng for DNA-based coatings func-
tionalized with 25 and 250 ng VEGF, respectively. The
subsequent sustained VEGF release would then approximate
0.5 and 5 ng per week, respectively. Although the exact re-
leased amounts are not clear, the amounts released in the
collected release media are apparently sufficient for an effect
on endothelial cell migration.
Several animal models for studying angiogenesis have
been described in detail, including dorsal skinfold cham-
bers23 and ear pinnae;24 however, these models have limita-
tions regarding implant size,25 which impedes their use for
our implants. Additionally, because the focus of our study
was to monitor vascularity effects of the peri-implant tissue
of subcutaneous implants, we used a simple subcutaneous
implantation model in rats. Inevitably, this simple approach
for the detection of effects on vascularization has several
drawbacks. For instance, the confinement of the area for
evaluation of the effects of VEGF on vascularization was
difficult to standardize. In contrast to previous studies, in
which vascularization was determined in porous implants,26,27
the use of solid implants is associated with concessions in
peri-implant area. The excision of the implants, allowing
deformations of the fibrous capsule and surrounding tissue
during subsequent histological processing further hampered
standardization of the peri-implant area. Nevertheless, the
approach used in this study allows the comparison of vessel
density in the peri-implant area, in which the maximum dis-
tance of vessels to the implant surface approximates 600mm
(image height of aSMA-stained sections& 650mm). The
results show no significant effects of individual VEGF-
functionalized DNA-based coatings on peri-implant vessel
density. However, significantly greater peri-implant vascu-
larity was observed in VEGF-functionalized DNA-based
coatings than in controls and non-functionalized DNA-based
coatings. Furthermore, a significant decrease in vascularity
from 1 to 3 weeks after implantation was observed in tissue
surrounding non-functionalized DNA-based coatings. This
observation might be related to the effect of DNA-based
coatings on fibroblasts,9,10 which form the fibrous capsule,
and subsequent intercellular signaling between fibroblasts and
cells in their surroundings. However, the actual cause for this
observation remains unclear and should be addressed in future
experiments.
Although the functionalization of DNA-based coatings in
this study was restricted to a single angiogenic factor, con-
siderable debate is ongoing on the necessity for combined
growth factor delivery for angiogenesis and vessel maturation.
Indeed, synergistic effects of combined administration of
VEGF and basic fibroblast growth factor have been demon-
strated on collateral circulation in a hind limb ischemia
model.28 Additionally, Peattie et al. demonstrated enhance-
ment of angiogenic responses in a murine ear pinnae model
using dual delivery of VEGF and keratinocyte growth fac-
tor.29 Such combined delivery vehicles could also be fabri-
cated using DNA-based coatings, because the mechanism
of fabrication has been demonstrated to be applicable for
compartmentalization of such polyelectrolyte multilayers,30
which would allow temporal control over growth factor
release.
CONCLUSION
This study demonstrates that the functionalization of DNA-
based coatings with the pro-angiogenic factor VEGF results
in greater proliferation and migration of endothelial cells
in vitro, indicating that the VEGF retained its biological ac-
tivity. In an in vivo implantation experiment in rats, greater
vascularization of the peri-implant tissue surrounding VEGF-
functionalized DNA-based coatings was observed.
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